Biosensors at TCT 2016

Washington, DC October 29 - November 2, 2016.
Transcatheter Cardiovascular Therapeutics (TCT)
Is the world's largest educational meeting specializing in interventional
cardiovascular medicine, attracting close to 12’000 delegates from across the globe.
The Biosensors International booth will be located on level 2, booth number 1808.
For more information about the congress : http://www.crf.org/tct

In Evidence Based Medicine We Trust!
At TCT 2016, Biosensors brings more clinical evidence to support patient treatment options

EGO BIOFREEDOM QCA evidence

EGO BIOFREEDOM
Largest BioFreedom cohort investigated for angiographic outcomes by QCA
Saturday October 29, 2016 - Presented by: Ricardo Costa
EGO Biofreedom is an independent Investigator Sponsored Study supported through a Research Grant from Biosensors International Group, Ltd.

LEADERS FREE 2 years follow-up
Looking for more dedicated evidence to support the treatment
of your High Bleeding Risk patients?

2 years data follow-up from the landmark LEADERS FREE trial
Sunday October 30, 2016 - Speaker: Philip M. Urban
Get more details about LEADERS FREE 2 years follow-up

NOBLE primary endpoint
NOBLE physician initiated trial
will bring new evidence on the treatment of the Left Main

Learn more about the PIT
Monday October 31, 2016 - Speaker: Evald H. Christiansen
NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents
and Bypass Graft Surgery in Selected Patients with Left Main Coronary Artery Disease